📊 CANF Key Takeaways
Is Can-Fite BioPharma Ltd. (CANF) a Good Investment?
Unable to perform fundamental analysis due to missing financial data. Company shows no available revenue, profitability metrics, balance sheet data, or cash flow information, indicating either pre-revenue status or severe data reporting issues. The lack of any measurable financial metrics prevents assessment of business viability or financial health.
Can-Fite BioPharma’s fundamentals remain weak: revenue is minimal and declining, while operating losses and cash burn continue to materially exceed its revenue base. The balance sheet still shows no meaningful long-term debt, but liquidity depends on repeated equity raises and management’s cost-deferral plans rather than internally generated cash flow, which points to low-quality growth and high financing risk.
Why Buy Can-Fite BioPharma Ltd. Stock? CANF Key Strengths
- Operates in pharmaceutical sector with potential for high-value drug development
- Listed on NYSE indicating some market capitalization threshold met
- Presence of insider activity historically (though none in last 90 days)
- No meaningful long-term debt and relatively modest absolute liabilities
- Some recurring licensing and deferred-revenue base from partnership agreements
- R&D spending remains focused on advancing multiple clinical programs
CANF Stock Risks: Can-Fite BioPharma Ltd. Investment Risks
- No revenue reported - business model viability unverified
- Complete absence of profitability metrics suggests unprofitable operations
- No cash flow or balance sheet data available for financial health assessment
- Zero insider Form 4 filings in last 90 days suggests lack of insider confidence
- Data freshness unavailable - financial information cannot be dated or verified as current
- Persistent operating losses with revenue far too small to support the cost structure
- Ongoing negative operating cash flow creates continued dependence on external financing
- Shareholder equity has been eroding and funding has relied heavily on repeated share issuance
Key Metrics to Watch
- Revenue generation and YoY growth rates
- Cash position and burn rate given pre-revenue status
- Clinical trial progress and regulatory milestones for pipeline drugs
- Operating expenses and path to profitability timeline
- Quarterly operating cash burn versus cash and equivalents runway
- Licensing revenue and milestone inflows relative to R&D and G&A expense growth
Can-Fite BioPharma Ltd. (CANF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CANF Profit Margin, ROE & Profitability Analysis
CANF vs Healthcare Sector: How Can-Fite BioPharma Ltd. Compares
How Can-Fite BioPharma Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Can-Fite BioPharma Ltd. Stock Overvalued? CANF Valuation Analysis 2026
Based on fundamental analysis, Can-Fite BioPharma Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Can-Fite BioPharma Ltd. Balance Sheet: CANF Debt, Cash & Liquidity
CANF Revenue Growth, EPS Growth & YoY Performance
CANF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Can-Fite BioPharma Ltd. (CIK: 0001536196)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CANF
What is the AI rating for CANF?
Can-Fite BioPharma Ltd. (CANF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 52% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CANF's key strengths?
Claude: Operates in pharmaceutical sector with potential for high-value drug development. Listed on NYSE indicating some market capitalization threshold met. ChatGPT: No meaningful long-term debt and relatively modest absolute liabilities. Some recurring licensing and deferred-revenue base from partnership agreements.
What are the risks of investing in CANF?
Claude: No revenue reported - business model viability unverified. Complete absence of profitability metrics suggests unprofitable operations. ChatGPT: Persistent operating losses with revenue far too small to support the cost structure. Ongoing negative operating cash flow creates continued dependence on external financing.
What is CANF's revenue and growth?
Can-Fite BioPharma Ltd. reported revenue of N/A.
Does CANF pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
Where can I find CANF SEC filings?
Official SEC filings for Can-Fite BioPharma Ltd. (CIK: 0001536196) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CANF's EPS?
Can-Fite BioPharma Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CANF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Can-Fite BioPharma Ltd. has a SELL rating with 52% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CANF stock overvalued or undervalued?
Valuation metrics for CANF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CANF stock in 2026?
Our dual AI analysis gives Can-Fite BioPharma Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CANF's free cash flow?
Can-Fite BioPharma Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CANF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).